Amitriptyline
- amitriptyline
- 50-48-6
- Amitriptylin
- Damitriptyline
- Triptanol
- Create:2005-03-25
- Modify:2025-01-18
- Amineurin
- Amitrip
- Amitriptylin beta
- Amitriptylin Desitin
- Amitriptylin neuraxpharm
- Amitriptylin RPh
- Amitriptylin-neuraxpharm
- Amitriptyline
- Amitriptyline Hydrochloride
- Amitrol
- Anapsique
- Apo Amitriptyline
- Apo-Amitriptyline
- Damilen
- Desitin, Amitriptylin
- Domical
- Elavil
- Endep
- Laroxyl
- Lentizol
- Novoprotect
- RPh, Amitriptylin
- Saroten
- Sarotex
- Syneudon
- Triptafen
- Tryptanol
- Tryptine
- Tryptizol
- amitriptyline
- 50-48-6
- Amitriptylin
- Damitriptyline
- Triptanol
- Flavyl
- Seroten
- Proheptadiene
- Lantron
- Triptisol
- Tryptanol
- Adepress
- Adepril
- Damilen
- Amitryptiline
- Triptilin
- Redomex
- Amitriprolidine
- Laroxyl
- Amitriptilina
- Amytriptylin
- Amitriptylinum
- Amitryptyline
- Damilan
- Laroxil
- Ro 4-1575
- MK 230
- Sarotex
- Amitriptylinum [INN-Latin]
- Amitriptilina [INN-Spanish]
- 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
- 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
- CCRIS 9174
- HSDB 3007
- 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene
- 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine
- N 750
- EINECS 200-041-6
- BRN 2217885
- CHEBI:2666
- Amitriptyline (INN)
- UNII-1806D8D52K
- 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene
- 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin
- 5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl-
- CHEMBL629
- 1806D8D52K
- 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
- 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene
- 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
- 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-
- 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine
- DTXSID7022594
- EC 200-041-6
- 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene
- 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine
- 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-
- Amytriptiline
- Elanil
- Amitriptylin [German]
- 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene
- Amitriptilina [Italian]
- AMITRIPTYLINE [INN]
- Amitriptylinum (INN-Latin)
- 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
- 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N,N-dimethyl-
- Amitriptilina (INN-Spanish)
- Amitriptyline [INN:BAN]
- N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
- AMITRIPTYLINE (MART.)
- AMITRIPTYLINE [MART.]
- AMITRIPTYLINE (USP IMPURITY)
- AMITRIPTYLINE [USP IMPURITY]
- 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene
- 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene
- 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta5,gamma-propylamine
- 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
- 5H-Dibenzo[a,d]cycloheptene-.delta.5,.gamma.-propylamine, 10,11-dihydro-N,N-dimethyl-
- TP0
- Laroxyl (TN)
- NCGC00015095-09
- CAS-549-18-8
- Elani
- 3-(10,11-dihydro-5H-dibenzo(a,d)(7)annulen-5-ylidene)-N,N-dimethylpropan-1-amine
- 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
- Domical (Salt/Mix)
- Laroxyl (Salt/Mix)
- Lentizol (Salt/Mix)
- Vanatrip (Salt/Mix)
- Triptizol (Salt/Mix)
- Amitriptylinum (Latin)
- Spectrum_000044
- Prestwick0_000074
- Prestwick1_000074
- Prestwick2_000074
- Prestwick3_000074
- Spectrum2_000101
- Spectrum3_000298
- Spectrum4_000146
- Spectrum5_000806
- Lopac-A-8404
- AMITRIPTYLINE [MI]
- SCHEMBL7824
- Lopac0_000112
- Oprea1_479304
- AMITRIPTYLINE [VANDF]
- BSPBio_000287
- BSPBio_001836
- GTPL200
- KBioGR_000592
- KBioGR_002261
- KBioSS_000424
- KBioSS_002262
- BIDD:GT0115
- DivK1c_000766
- SPBio_000082
- SPBio_002208
- AMITRIPTYLINE [WHO-DD]
- BPBio1_000317
- DTXCID502594
- KBio1_000766
- KBio2_000424
- KBio2_002261
- KBio2_002992
- KBio2_004829
- KBio2_005560
- KBio2_007397
- KBio3_001336
- KBio3_002741
- N06AA09
- cMAP_000001
- NINDS_000766
- 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene
- BCP09083
- HY-B0527
- PS01 - Amitriptyline/Nortriptyline
- BDBM50020712
- MK-230
- PDSP1_001564
- PDSP2_001548
- s5947
- STK525215
- 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene
- 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene
- AKOS000512694
- CCG-204207
- DB00321
- SDCCGSBI-0050100.P005
- 3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethyl-1-propanamine
- IDI1_000766
- MRF-0000533
- NCGC00015095-01
- NCGC00015095-02
- NCGC00015095-03
- NCGC00015095-04
- NCGC00015095-05
- NCGC00015095-06
- NCGC00015095-07
- NCGC00015095-08
- NCGC00015095-10
- NCGC00015095-11
- NCGC00015095-12
- NCGC00015095-14
- NCGC00015095-26
- NCGC00024433-04
- NCGC00183047-01
- 1ST10058
- DA-50424
- dimethyl({3-[(2Z)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene]propyl})amine
- SBI-0050100.P004
- 3B - Known Drug Blood Quantification Sample
- AB00514631
- AmitriptylineMK-230, N-750, Ro41575
- CS-0009498
- NS00000032
- C06824
- D07448
- Q58397
- AB00053417-12
- AB00053417_13
- AB00053417_14
- L001041
- W-109252
- BRD-K53737926-003-05-4
- BRD-K53737926-003-14-6
- BRD-K53737926-003-25-2
- BRD-K53737926-003-27-8
- 5-(3-Dimethylpropylidene)dibenzo(a,d)(1,4)cycloheptadiene
- NORTRIPTYLINE HYDROCHLORIDE IMPURITY F [EP IMPURITY]
- 5-(.gamma.-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene
- 5-(.gamma.-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
- 5-(3-Dimethylaminopropylidene)-10,11-dihyro-5h-dibenzo(a,d)cycloheptene
- 10,11-Dihydro-5-(.gamma.-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene
- 10,11-dihydro-N,N-dimethl-5H-dibenzo[a,d]cycloheptene-(delta(5, gamma))-propylamine
- 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-.DELTA.5,.gamma.-propylamine
- 3-(5,6-dihydrodibenzo[[?],[?]][7]annulen-11-ylidene)-N,N-dimethyl-propan-1-amine
- 5-(.gamma.-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
- 5-(.gamma.-Dimethylaminopropylidene)-5H-dibenzo(a,d)-10,11-dihydrocycloheptene
- 5H-Dibenzo(a,d)cyclopheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-n,n-dimethyl-
- N-[3-(10,11-DIHYDRO-5H-DIBENZO[A,D]CYCLOHEPTEN-5-YLIDEN)PROPYL]-N,N-DIMETHYLAMINE
- 3-(10,11-Dihydro-5H-dibenzo-[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine, hydrochloride
- 5H-Dibenzo(a,d)cycloheptene-.delta.(sup 5),.gamma.-propylamine, 10,11-dihydro-N,N-dimethyl-
- 5H-Dibenzo[a,d]cycloheptene-Delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl- (6CI,8CI) 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene
- dimethyl({3-[(2E)-tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene]propyl})amine
Medicines for depressive disorders
Medicines for other common symptoms in palliative care
58.0 99.99
202.0 3.10
203.0 2.40
91.0 2.40
218.0 2.10
58 99.99
202 3.10
91 2.40
203 2.40
218 2.10
191.0854 100
233.1324 99.29
117.07 79.55
218.1089 64.87
105.07 61.68
191.0853 100
117.0701 62.96
218.1085 53.75
203.0853 47.95
105.0701 47.85
278.191 999
279.1931 351
233.1316 48
280.196 27
234.1347 9
278.1902 999
233.1318 715
279.1933 204
191.0847 126
234.1353 111
58 999
202 31
91 24
203 24
218 21
91.0542 999
105.0699 657
117.0699 583
278.1904 464
115.0542 265
- Extracellular
- Membrane
Use (kg; approx.) in Germany (2009): >7500
Use (kg) in USA (2002): 17300
Consumption (g per capita; approx.) in Germany (2009): 0.0916
Consumption (g per capita) in the USA (2002): 0.0613
Excretion rate: 0.02
Calculated removal (%): 87.4
H301+H311+H331 (41.8%): Toxic if swallowed, in contact with skin or if inhaled [Danger Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]
H301 (41.8%): Toxic if swallowed [Danger Acute toxicity, oral]
H302 (56.7%): Harmful if swallowed [Warning Acute toxicity, oral]
H311 (41.8%): Toxic in contact with skin [Danger Acute toxicity, dermal]
H318 (41.8%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
H331 (41.8%): Toxic if inhaled [Danger Acute toxicity, inhalation]
H361 (41.8%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
H410 (41.8%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]
P203, P261, P262, P264, P264+P265, P270, P271, P273, P280, P301+P316, P301+P317, P302+P352, P304+P340, P305+P354+P338, P316, P317, P318, P321, P330, P361+P364, P391, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 67 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 3 (41.8%)
Acute Tox. 4 (56.7%)
Acute Tox. 3 (41.8%)
Eye Dam. 1 (41.8%)
Acute Tox. 3 (41.8%)
Repr. 2 (41.8%)
Aquatic Chronic 1 (41.8%)
Liver test abnormalities have been reported to occur in 10% to 12% of patients on amitriptyline, but elevations are uncommonly above 3 times the upper limit of normal. The aminotransferase abnormalities are usually mild, asymptomatic and transient, reversing even with continuation of medication. Rare instances of clinically apparent acute liver injury have been reported in patients on amitriptyline. The latency to onset is quite variable, ranging from 1 to 14 months of starting the medication. The reported pattern of serum enzyme elevations has varied from hepatocellular to cholestatic. An acute hepatitis-like syndrome with acute liver failure has been reported, as well as acute cholestatic hepatitis and prolonged jaundice compatible with vanishing bile duct syndrome. Signs or symptoms of hypersensitivity (rash, fever and eosinophilia) are frequent, but are usually mild and transient. Autoantibody formation is rare.
Likelihood score: B (highly likely cause of clinically apparent liver injury).
M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
◉ Summary of Use during Lactation
Milk levels of amitriptyline and its metabolites are low. Immediate side effects have not been reported and a limited amount of follow-up has found no adverse effects on infant growth and development. Amitriptyline use during breastfeeding would usually not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. A safety scoring system finds amitriptyline use to be possible with caution during breastfeeding. However, rare sedation has been reported in a neonate. Other agents with fewer active metabolites may be preferred when large doses are required or while nursing a newborn or preterm infant.
◉ Effects in Breastfed Infants
At least 23 infants have been reported to have been exposed to amitriptyline in breastmilk up to 2002 with no reports of adverse reactions with maternal dosages from 75 to 175 mg daily.
Follow-up for 1 to 3 years in a group of 20 breastfed infants whose mothers were taking a tricyclic antidepressant found no adverse effects on growth and development. One of the mothers whose infant was followed up at 18 months of age was taking amitriptyline 150 mg daily.
Two small controlled studies indicate that other tricyclic antidepressants have no adverse effect on infant development. In one of the studies, 2 mothers were taking amitriptyline 100 and 175 mg daily. One of the infants tested in the low normal range from birth and on repeat testing.
In another study, 25 infants whose mothers took a tricyclic antidepressant during pregnancy and lactation were tested formally between 15 to 71 months and found to have normal growth and development. Some of the mothers were taking amitriptyline.
A nursing mother was prescribed amitriptyline 10 mg daily for insomnia. After 3 days of the medication, her 15-day-old infant developed severe sedation and an estimated 80% decrease in breastfeeding because of the sedation. The infant was otherwise normal on examination. The drug was discontinued and symptoms decreased within 24 hours and were absent after 48 hours. Amitriptyline was restarted at 10 mg daily. The same effects reappeared in the infant and again disappeared by 48 hours after discontinuation of the drug. The infant’s sedation was probably caused by amitriptyline in breastmilk.
A case-control study in Israel compared 280 infants of nursing mothers taking long-term psychotropic drugs to the infants of 152 women taking antibiotics. Neonatal infant sleepiness was reported by 1 mother taking amitriptyline and none taking antibiotics.
◉ Effects on Lactation and Breastmilk
Amitriptyline has caused increased prolactin levels in nonpregnant, nonnursing patients. The clinical relevance of these findings in nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
An observational study looked at outcomes of 2859 women who took an antidepressant during the 2 years prior to pregnancy. Compared to women who did not take an antidepressant during pregnancy, mothers who took an antidepressant during all 3 trimesters of pregnancy were 37% less likely to be breastfeeding upon hospital discharge. Mothers who took an antidepressant only during the third trimester were 75% less likely to be breastfeeding at discharge. Those who took an antidepressant only during the first and second trimesters did not have a reduced likelihood of breastfeeding at discharge. The antidepressants used by the mothers were not specified.
A retrospective cohort study of hospital electronic medical records from 2001 to 2008 compared women who had been dispensed an antidepressant during late gestation (n = 575; amitriptyline n = 30) to those who had a psychiatric illness but did not receive an antidepressant (n = 1552) and mothers who did not have a psychiatric diagnosis (n = 30,535). Women who received an antidepressant were 37% less likely to be breastfeeding at discharge than women without a psychiatric diagnosis, but no less likely to be breastfeeding than untreated mothers with a psychiatric diagnosis.
In a study of 80,882 Norwegian mother-infant pairs from 1999 to 2008, new postpartum antidepressant use was reported by 392 women and 201 reported that they continued antidepressants from pregnancy. Compared with the unexposed comparison group, late pregnancy antidepressant use was associated with a 7% reduced likelihood of breastfeeding initiation, but with no effect on breastfeeding duration or exclusivity. Compared with the unexposed comparison group, new or restarted antidepressant use was associated with a 63% reduced likelihood of predominant, and a 51% reduced likelihood of any breastfeeding at 6 months, as well as a 2.6-fold increased risk of abrupt breastfeeding discontinuation. Specific antidepressants were not mentioned.
◈ What is amitriptyline?
Amitriptyline belongs to a class of medications known as tricyclic antidepressants. Amitriptyline is approved to treat depression. However, it ha#s also been used to treat pain, tinnitus (noise or ringing sounds in the ear), Irritable bowel syndrome, neuropathy (nerve damage) due to diabetes mellitus, and to treat and prevent migraine headaches. Amitriptyline has been sold under many different brand names. Some brand names are Amaril®, Amitrid®, Elavil®, Endep®, and Vanatrip®. Amitriptyline has also been sold in combination with other medications.Pregnancy might affect how the body breaks down this medication. For this reason, some people might need to have their medication doses changed as a pregnancy progresses. Your healthcare provider can discuss this with you, if needed.Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take this medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy. Some people might have a return of their symptoms (relapse) if they stop taking amitriptyline. If you plan to stop this medication, your healthcare provider may suggest that you slowly lower the dose instead of stopping all at once. Stopping this medication suddenly can cause some people to have withdrawal symptoms.
◈ I take amitrivptyline. Can it make it harder for me to get pregnant?
Studies have not been done to see if amitriptyline could make it harder to get pregnant.
◈ Does taking amitriptyline increase the chance for miscarriage?
Miscarriage is common and can occur in any pregnancy for many different reasons. Based on the studies reviewed, it is not known if amitriptyline increases the chance for miscarriage. However, depression itself might increase the chance for miscarriage.
◈ Does taking amitriptyline increase the chance of birth defects?
Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. Based on the studies reviewed, it is not known if amitriptyline increases the chance for birth defects above the background risk. A small number of human studies have not found a higher chance for birth defects with doses of amitriptyline used for treatment of depression.
◈ Does taking amitriptyline in pregnancy increase the chance of other pregnancy related problems?
One report found a small increased chance of preeclampsia (a pregnancy related condition that can cause symptoms such as high blood pressure and kidney problems in the pregnant person) when amitriptyline was used in the second and third trimester of pregnancy. Studies have not been done to see if amitriptyline increases the chance for other pregnancy-related problems such as preterm delivery (birth before week 37) or low birth weight (weighing less than 5 pounds, 8 ounces [2500 grams] at birth). However, research has shown that when depression is left untreated during pregnancy, there could be an increased chance for pregnancy complications. This makes it hard to know if it is the medication, untreated depression or factors that are increasing the chance for these problems. For more information, please see our fact sheet on Depression at https://mothertobaby.org/fact-sheets/depression-pregnancy/.
◈ I need to take amitriptyline throughout my entire pregnancy. Will it cause withdrawal symptoms in my baby after birth?
Studies have not been done to see if amitriptyline use in pregnant might lead to withdrawal or toxicity in a newborn soon after delivery. There is one case report of an infant who had temporary withdrawal symptoms after being exposed throughout pregnancy. The infant and the mother were found to have high blood levels of amitriptyline.Some babies exposed to other tricyclic antidepressant class medications in pregnancy have been reported to have withdrawal symptoms in the newborn period. The symptoms seen during the first month of life included colic, low oxygen levels, breathing problems, and irritability. If a baby developed these symptoms, in most cases the symptoms would go away in a few days without any long-term health effects.
◈ Does taking amitriptyline in pregnancy affect future behavior or learning for the child?
One study looking at 29 children exposed to amitriptyline during pregnancy did not find any behavioral or learning problems.
◈ Breastfeeding while taking amitriptyline:
Amitriptyline gets into breast milk in small amounts. There are several reports of the use of amitriptyline being used during breasting. No side effects in nursing infants have been reported with a dose between 75 mg to 175 mg per day.There was one report of a person who was taking 10 mg of amitriptyline per day while breastfeeding. The breastfeeding baby (15 days old) was reported to be very sleepy. When the medication was stopped, the infant’s symptom resolved.If you suspect that your baby has symptoms of sleepiness or sedation, or have other concerns, contact the child’s healthcare provider. Be sure to talk with your healthcare providers about your breastfeeding questions
◈ If a male takes amitriptyline, could it affect fertility (ability to get partner pregnant) or increase the chance of birth defects?
In some studies, it was reported that amitriptyline lowered sex drive and caused sexual dysfunction in males, which may make it harder to get a partner pregnant. These problems can also be side effects of untreated depression. Studies have not been done to see if amitriptyline could increase the chance of birth defects. In general, exposures that fathers or sperm donors have are unlikely to increase the risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=KRMDCWKBEZIMAB-UHFFFAOYSA-N
- Avoid alcohol.
- Avoid St. John's Wort.
- Limit caffeine intake.
- Take with food. Food reduces irritation.
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusAmitriptyline [INN:BAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000050486ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useAmitriptylinehttps://www.drugbank.ca/drugs/DB00321
- EPA DSSToxAmitriptylinehttps://comptox.epa.gov/dashboard/DTXSID7022594CompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeAmitriptylinehttps://chem.echa.europa.eu/100.000.038Amitriptyline (EC: 200-041-6)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/14353
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)AMITRIPTYLINEhttps://pubchem.ncbi.nlm.nih.gov/source/hsdb/3007
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citingAmitriptylinehttp://www.hmdb.ca/metabolites/HMDB0014466HMDB0014466_cms_27619https://hmdb.ca/metabolites/HMDB0014466#spectra
- New Zealand Environmental Protection Authority (EPA)LICENSEThis work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence.https://www.epa.govt.nz/about-this-site/general-copyright-statement/
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ChEBI
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LiverTox
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licenceAMITRIPTYLINEhttps://platform.opentargets.org/drug/CHEMBL629
- Toxin and Toxin Target Database (T3DB)LICENSET3DB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (T3DB) and the original publication.http://www.t3db.ca/downloadsAmitriptylinehttp://www.t3db.ca/toxins/T3D2480
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/AMITRIPTYLINENORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsN4-PHENYLETHOXYCYTIDINE-5'-TRIPHOSPHATEhttps://www.dgidb.org/drugs/iuphar.ligand:6200
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)Amitriptylinehttps://idrblab.net/ttd/data/drug/details/D0Y5UG
- Drug Induced Liver Injury Rank (DILIrank) DatasetLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Drugs and Lactation Database (LactMed)Amitriptylinehttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM312/
- Mother To Baby Fact SheetsLICENSECopyright by OTIS. This work is available under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license (CC BY-NC-ND 3.0).https://www.ncbi.nlm.nih.gov/books/about/copyright/
- WHO Model Lists of Essential MedicinesLICENSEPermission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license.https://www.who.int/about/policies/publishing/copyrightAmitriptylinehttps://list.essentialmeds.org/medicines/19
- EU Clinical Trials Register
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- NIST Mass Spectrometry Data CenterLICENSEData covered by the Standard Reference Data Act of 1968 as amended.https://www.nist.gov/srd/public-lawAmitriptylinehttp://www.nist.gov/srd/nist1a.cfm
- SpectraBaseAmitriptylinehttps://spectrabase.com/spectrum/LW3W6aYLWlmAmitriptylinehttps://spectrabase.com/spectrum/Ec5HAwnkfKcAmitryptylinehttps://spectrabase.com/spectrum/GdSXAcIHCck
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- Kruve Lab, Ionization & Mass Spectrometry, Stockholm Universityamitriptyline
- MassBank Europe
- Metabolomics Workbench
- Natural Product Activity and Species Source (NPASS)
- NIPH Clinical Trials Search of Japan
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlamitriptylinehttps://rxnav.nlm.nih.gov/id/rxnorm/704
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/Amitriptylinehttps://www.whocc.no/atc_ddd_index/?code=N06AA09
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policiesamitriptylinehttps://www.pharmgkb.org/chemical/PA448385
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/aboutamitriptylinehttps://pharos.nih.gov/ligands/V5NVUP34ATWH
- Protein Data Bank in Europe (PDBe)
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- USGS Health-Based Screening Levels for Evaluating Water-Quality DataLICENSEhttps://www.usgs.gov/legal
- Wikidataamitriptylinehttps://www.wikidata.org/wiki/Q58397
- WikipediaCarbofuranhttps://en.wikipedia.org/wiki/CarbofuranAmitriptylinehttps://en.wikipedia.org/wiki/Amitriptyline
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlAmitriptylinehttps://www.ncbi.nlm.nih.gov/mesh/68000639Adrenergic Uptake Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68018759Antidepressive Agents, Tricyclichttps://www.ncbi.nlm.nih.gov/mesh/68000929Analgesics, Non-Narcotichttps://www.ncbi.nlm.nih.gov/mesh/68018712
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- EPA Substance Registry ServicesEPA SRS List Classificationhttps://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 403383103https://pubchem.ncbi.nlm.nih.gov/substance/403383103
- NCBI